ACAD

ACADIA PHARMACEUTICALS INC

8 filings tracked

healthcarebiotechnologyMID ($2B-10B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bearishMay 29

Approval of 5.2 million additional shares for equity incentives increases potential dilution.

dilution risk

60%

neutralMay 29

Re-election of Class I directors confirms leadership continuity despite some shareholder dissent.

management change

30%

bearishMay 7

Swung from an operating profit of $19.3M to an operating loss of $4.6M year-over-year.

earnings miss

60%

bearishMay 7

SG&A expenses grew 35% YoY, significantly outpacing revenue growth of 9.7%.

margin compression

40%

bullishMay 7

Net product sales grew 9.7% to $268.1 million driven by NUPLAZID and DAYBUE.

earnings beat

50%

bearishMay 7

Swung from an operating profit of $19.3M to an operating loss of $4.6M year-over-year.

earnings miss

60%

bearishMay 7

SG&A expenses grew 35% YoY, significantly outpacing revenue growth of 9.7%.

margin compression

40%

bullishMay 7

Net product sales grew 9.7% to $268.1 million driven by NUPLAZID and DAYBUE.

earnings beat

50%

bearishMay 7

Swung from an operating profit of $19.3M to an operating loss of $4.6M year-over-year.

earnings miss

60%

bearishMay 7

SG&A expenses grew 35% YoY, significantly outpacing revenue growth of 9.7%.

margin compression

40%

bullishMay 7

Net product sales grew 9.7% to $268.1 million driven by NUPLAZID and DAYBUE.

earnings beat

50%

bearishMay 7

Swung from an operating profit of $19.3M to an operating loss of $4.6M year-over-year.

earnings miss

60%

bearishMay 7

SG&A expenses grew 35% YoY, significantly outpacing revenue growth of 9.7%.

margin compression

40%

bullishMay 7

Net product sales grew 9.7% to $268.1 million driven by NUPLAZID and DAYBUE.

earnings beat

50%

bearishMay 7

Swung from an operating profit of $19.3M to an operating loss of $4.6M year-over-year.

earnings miss

60%

bearishMay 7

SG&A expenses grew 35% YoY, significantly outpacing revenue growth of 9.7%.

margin compression

40%

bullishMay 7

Net product sales grew 9.7% to $268.1 million driven by NUPLAZID and DAYBUE.

earnings beat

50%

bearishMay 7

Swung from an operating profit of $19.3M to an operating loss of $4.6M year-over-year.

earnings miss

60%

bearishMay 7

SG&A expenses grew 35% YoY, significantly outpacing revenue growth of 9.7%.

margin compression

40%

bullishMay 7

Net product sales grew 9.7% to $268.1 million driven by NUPLAZID and DAYBUE.

earnings beat

50%

bearishMay 7

Swung from an operating profit of $19.3M to an operating loss of $4.6M year-over-year.

earnings miss

60%

bearishMay 7

SG&A expenses grew 35% YoY, significantly outpacing revenue growth of 9.7%.

margin compression

40%

bullishMay 7

Net product sales grew 9.7% to $268.1 million driven by NUPLAZID and DAYBUE.

earnings beat

50%

Filing History

8-KMay 29, 2026

The May 29, 2026, 8-K filing confirms that Acadia Pharmaceuticals has successfully passed its annual meeting, ratifying its board and expanding its equity pool. While the administrative victory provides a stable runway for management, the trade-off is a potential increase in share count that could weigh on per-share value. Investors must now weigh the benefit of a talent-rich organization against the risk of equity dilution. The overall impact is a stabilization of leadership, though the market will remain sensitive to how these new incentives are deployed relative to the company's actual cash burn and clinical progress.

10-QMay 7, 2026

The Q1 2026 filing presents a company at a critical crossroads between aggressive scaling and operational efficiency. On one hand, the top-line growth and massive cash reserves provide a level of stability rarely seen in mid-cap biotech. The successful launch of new formulations and the steady climb in unit sales for both core products suggest that the market demand remains robust. However, the transition to an operating loss highlights the precarious nature of this growth. Investors must weigh the ability to sustain high SG&A spend against the potential for long-term revenue compounding. The overarching impact of the filing is a shift in the investment thesis from one of pure clinical binary risk to one of commercial execution and margin management. The next twelve months will be decisive as the company attempts to translate its revenue growth into sustainable operating leverage while navigating complex international regulatory hurdles.